Skip to Main Content

GLTO logo

Galecto, Inc. Common Stock

N/A USD
N/A
N/A
...
Chart
Financials
Description
GLTO Company Description

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

GLTO Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view GLTO Smart Score

Score Breakdown
GLTO Company Description

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show Less

Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of GLTO by members of U.S. Congress

  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login

Recently reported changes by institutional investors

Quiver Logo

Sign Up for Access

Sign Up or Login

Quarterly net insider trading by GLTO's directors and management

Quiver Logo

Sign Up for Access

Sign Up or Login

Government lobbying spending instances

  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
U.S. Patents

New patents grants

  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
Government Contracts

Federal grants, loans, and purchases

  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
WallStreetBets

Number of mentions of GLTO in WallStreetBets Daily Discussion

Quiver Logo

Sign Up for Access

Sign Up or Login
GLTO News

Recent insights relating to GLTO

  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
  • Patent Title: Hidden Quiver Patent Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
CNBC Recommendations

Recent picks made for GLTO stock on CNBC

  • Pick: Hidden Pick Title Hidden Date
  • Pick: Hidden Pick Title Hidden Date
  • Pick: Hidden Pick Title Hidden Date
  • Pick: Hidden Pick Title Hidden Date
  • Pick: Hidden Pick Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
Top ETF Holders

ETFs with the largest estimated holdings in GLTO

  • ETF: Hidden ETF Title Hidden Date
  • ETF: Hidden ETF Title Hidden Date
  • ETF: Hidden ETF Title Hidden Date
  • ETF: Hidden ETF Title Hidden Date
  • ETF: Hidden ETF Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
Corporate Flights

Flights by private jets registered to GLTO

  • Flight Title: Hidden Quiver Flight Title Hidden Date
  • Flight Title: Hidden Quiver Flight Title Hidden Date
  • Flight Title: Hidden Quiver Flight Title Hidden Date
  • Flight Title: Hidden Quiver Flight Title Hidden Date
  • Flight Title: Hidden Quiver Flight Title Hidden Date
Quiver Logo

Sign Up for Access

Sign Up or Login
Back To Top